MABEL: Cetuximab with irinotecan in advanced CRC [colorectal cancer] (V1.0) & AM 1 (V1.0). Open, uncontrolled, multicentre, phase II study

Trial Profile

MABEL: Cetuximab with irinotecan in advanced CRC [colorectal cancer] (V1.0) & AM 1 (V1.0). Open, uncontrolled, multicentre, phase II study

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2006

At a glance

  • Drugs Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MABEL
  • Most Recent Events

    • 07 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top